Author

Peter Irving

INTESTINAL ULTRASOUND INSTEAD OF ENDOSCOPY: LARGE POTENTIAL ROLE AND COST SAVINGS
INTESTINAL ULTRASOUND INSTEAD OF ENDOSCOPY: LARGE POTENTIAL ROLE AND COST SAVINGS

Peter Irving  et al.

IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Peter Irving  et al.

A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE
A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE

Peter Irving  et al.

GAMMA DELTA T CELL SELECTION BY BUTYROPHILIN-LIKE (BTNL) PROTEINS IS A CONSERVED TRAIT LIMITING IBD PROGRESSION
GAMMA DELTA T CELL SELECTION BY BUTYROPHILIN-LIKE (BTNL) PROTEINS IS A CONSERVED TRAIT LIMITING IBD PROGRESSION

Peter Irving  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Peter Irving  et al.

COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE
COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE

Peter Irving  et al.

HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY
HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY

Peter Irving  et al.

HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ IN THE SEAVUE STUDY
HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ IN THE SEAVUE STUDY

Peter Irving  et al.

SURGICAL DOWNGRADING OF INFLAMMATORY BURDEN IN CROHN’S DISEASE OPTIMISES ANTI-TNF PHARMACOKINETICS
SURGICAL DOWNGRADING OF INFLAMMATORY BURDEN IN CROHN’S DISEASE OPTIMISES ANTI-TNF PHARMACOKINETICS

Peter Irving  et al.

Item 21 - 29 / 29
1
2